Half-life, steady state, and accumulation worked through — a second dataset posts 31–60
This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
Metabolism for peptide drugs is proteolytic rather than hepatic in the usual sense, which is why the cytochrome interaction questions that dominate small-molecule pharmacology mostly do not apply.
I will take the caveat as seriously as the claim, which is the point of putting it there.
Worth separating two things that post #32 runs together.
Taking Half-life seriously for a moment rather than deflecting: the honest position is that the community has observations and no controlled comparison, and those two things support very different sentences.
Narrowing post #34, because the general version has more than one answer.
Albumin binding: semaglutide binds albumin through a fatty side chain, which sequesters the free form and extends the half-life. Tirzepatide also has albumin binding (different mechanism) which extends its half-life compared to an unmodified peptide.
A qualification I should have led with rather than closed on.
My experience of Half-life contradicts the reply above. I am posting it as a data point rather than as a refutation, because one person's experience is exactly that.
Post #36 and I disagree about the size of the effect, not about the direction.
What I would want before treating Half-life as settled: the method, the sample, and whether anyone tried to find the opposite result. Two of the three are usually missing.
Confirming post #38 from a second method, which matters more than confirming it from a second person.
Where two sources give different half-lives, check the study design before deciding either is wrong. Sampling duration, assay sensitivity and population all move the number.
The variance between people here is larger than the effect being discussed.
I had written a reply contradicting post #36 and deleted it. Here is what survived.
Subcutaneous absorption is the rate-limiting step for most of these compounds, which is why the apparent half-life is absorption-limited rather than elimination-limited.
Written in the hope of being told what I have missed.
A pharmacokinetic model fitted to trial data describes the population studied. Applying it to somebody outside the enrolled range is an extrapolation, and the model will not tell you it is.
The disagreement above is smaller than it looks once the terms are fixed.
If you are new and reading this thread for the answer to Half-life: the answer is conditional, the conditions are in the third reply, and the rest of the thread is worth skipping.
Same experience here, different supplier, so it is at least not unique to one of them.
Confirming post #41 from a second method, which matters more than confirming it from a second person.
Half-life determines how quickly concentration approaches steady state and does not determine what the steady-state concentration is. Dose and clearance determine that.
I would rather say I do not know than round it up to an answer.
Worth separating two things that post #41 runs together.
Something worth flagging about Half-life: the strongest-sounding claims in this thread are the ones with no source attached, which is the usual pattern and not a coincidence.
Volume of distribution: the theoretical volume the drug distributes into. For albumin-binding compounds, volume is reduced compared to drugs that do not bind protein. That is relevant to understanding how much free drug is available.
I am confident about the direction and much less about the magnitude.
Loading doses are not used in this class and the pharmacokinetic reason is tolerability rather than efficacy. A loading dose would reach steady state faster and would be intolerable.
Reframing Half-life slightly, because I think the disagreement is about the question rather than the answer. If the question is "does it happen", yes. If it is "how often", nobody here knows.
Adding what did not work for me on Half-life, since the failures never get written up and they are half the useful information.
Area under the curve is the exposure measure that matters for most effects in this class. Peak concentration matters more for tolerability.
Metabolism for peptide drugs is proteolytic rather than hepatic in the usual sense, which is why the cytochrome interaction questions that dominate small-molecule pharmacology mostly do not apply.
That is my reading. Someone else read the same page differently and was reasonable.
Confirming post #52 from a second method, which matters more than confirming it from a second person.
Accumulation at steady state: with a week-long half-life, steady-state concentration is reached around 4 to 5 half-lives (about 4 to 5 weeks). Before that, concentration is rising with each dose. The clinical implication: escalating before 4 weeks means escalating before steady state.
Worth checking against a second source before it gets quoted onward.
I had written a reply contradicting post #51 and deleted it. Here is what survived.
Steady state is approached in roughly four to five half-lives. For a compound with a week-long half-life that is four to five weeks, which is where the escalation interval in the trials comes from.
Happy to expand any of that if it is the useful part.
A note on how Half-life gets discussed rather than on Half-life itself: the confident posts get the replies and the careful ones get ignored, and the careful ones have been right more often.
Post #55 is right about the mechanism and I think understates the practical bit.
I read the earlier replies on Half-life twice before writing this, because I had assumed the opposite and wanted to be sure I was disagreeing with what was said rather than what I expected.
A pharmacokinetic model fitted to trial data describes the population studied. Applying it to somebody outside the enrolled range is an extrapolation, and the model will not tell you it is.
Narrowing post #57, because the general version has more than one answer.
Terminal half-life estimated from a short sampling window underestimates the true value. That is a common source of discrepant figures between sources.
I have left out the parts I could not verify.
Half-life: semaglutide ≈ 165–184 hours (about a week). Tirzepatide ≈ 5 days. Liraglutide ≈ 13 hours. The half-life determines how much accumulation happens at steady state and how long it takes to clear after stopping.